Skip to main content

Table 1 Demographics and clinical characteristics of participants before and after propensity score matching

From: Change in cognitive function according to cholinesterase inhibitor use and amyloid PET positivity in patients with mild cognitive impairment

 

Before matching

p value

After matching

p value

ChEI user (n = 73)

ChEI non-user (n = 38)

ChEI user (n = 25)

ChEI non-user (n = 25)

Age, years

70.8 ± 8.7

71.6 ± 7.5

0.608

71.0 ± 8.8

70.7 ± 8.2

0.908

Female

45 (61.6)

22 (57.9)

0.427

15 (60.0)

15 (60.0)

1.000

Education, years

11.4 ± 4.7

13.2 ± 3.8

0.045

12 [9; 16]

14 [10; 16]

0.889

Amyloid PET positivity

53 (72.6)

17 (44.7)

0.004

14 (56.0)

14 (56.0)

1.000

Baseline MMSE

23.4 ± 2.9

26.3 ± 2.3

0.000

25.0 [24.0; 27.0]

26.0 [24.0; 27.0]

0.709

Baseline CDR SOB

2.5 ± 1.1

1.4 ± 0.8

0.000

1.5 [1.0; 3.0]

1.5 [1.0; 2.0]

0.738

APOEε4 carrier*

33 (62.3)

11 (42.3)

0.076

15 (60.0)

5 (31.2)

0.012

Cholinesterase inhibitor

 Donepezil

70 (95.9)

  

24 (0.96)

  

 Rivastigmine

3 (4.1)

  

1 (0.04)

  
  1. Data are presented as the mean ± standard deviation, median [interquartile range], or n (%)
  2. *There were 35 missing values among 111 patients from the unmatched cohort and 15 missing values among 50 patients from the matched cohort